Hepatitis B and C virus infection and risk of haematological malignancies.

Aldo Marrone, Marco Ciotti, Luca Rinaldi, Luigi Elio Adinolfi, Marc Ghany

Journal: Journal of viral hepatitis 2021;27(1):4-12

PMID: 31325404

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are classified as oncogenic human viruses. Chronic HBV and HCV infections are associated with higher risk of haematological malignancy development. Direct and indirect oncogenic mechanisms have been demonstrated for both HBV and HCV in several studies. HCV and overt/occult HBV infections in patients with oncohaematological disease constitute an impediment and a threat during immunosuppressive chemotherapy treatment. We review the HBV and HCV oncogenic mechanisms and the impact and the safety of antiviral treatment in patients with haematological malignancies.

Address: Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.; Laboratory of Clinical Microbiology and Virology, Polyclinic Tor Vergata Foundation, Rome, Italy.; Liver Diseases Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA.

DOI: 10.1111/jvh.13183

Link outs

Free resources

Medical:

https://medlineplus.gov/hepatitisc.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antiviral Agents, Hematologic Neoplasms, Hepatitis B, Hepatitis C, Hepatitis C, Chronic, Humans, Risk Factors, Virus Activation